drugset / Trial / NCT05525247
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination with gemcitabine, in patients with various advanced solid tumors.
Timeline
- Start
- 2022-12-21
- Primary completion
- 2025-08-26
- Completion
- 2025-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SLC-3010 | Unknown | — | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |